基本信息
浏览量:0
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
APL obtained his PhD at the Centro de Investigaciones Biológicas (CSIC, Madrid, Spain) under the supervision of Prof. Dr. Guillermo Giménez Gallego in 1995. After that, he moved to the Netherlands (EMBO and Marie Sklodowska-Curie grants) to work as a postdoctoral researcher with Prof. Dr. Cees Hilbers at the Radboud Universiteit (Nijmegen, The Netherlands) where he pursued further training in molecular biology, protein chemistry and NMR spectroscopy. Later on, he obtained a permanent position as an Associate Scientist at the Ontario Institute for Cancer Research (Princess Margaret Hospital, Toronto, Canada), the canadian reference centre for cancer treatment, where he worked in the structural characterization of oncoproteins and tumor suppressors, as well as in the development of new technologies for structural genomics. After declining different academic positions at the USA (University of Maryland, University of Wisconsin), APL accepted a position as an Associate Principal Scientist in a pharmaceutical company, AstraZeneca, in Alderley Park (Manchester, United Kingdom), the biggest research centre of this company in the oncology area. During that time, his efforts focused on the structural characterization of pharmaceutically relevant targets, and on the design of drugs using NMR and computational chemistry studies. Moreover, APL belonged to a core group within the company responsible for evaluating and selecting targets involved in cell invasion and metastasis. APL was recruited in 2005 by the Centro de Investigación Príncipe Felipe (CIPF, Valencia, Spain) to lead, as a Principal Investigator, the Structural Biochemistry Laboratory and the NMR facility. In may 2015, APL joined the Instituto de Investigación Sanitaria La Fe (Valencia, Spain) as Director of the Drug Discovery Unit and, at the same time, led the Joint Unit in Clinical Metabolomics CIPF/IIS La Fe. Four years later, APL was offered different senior management (Director of Translational Research, Deputy Director – november 2020 –) and scientific (Director of the Molecular Therapeutics Program, Senior Investigator of the Medicinal Chemistry laboratory) positions at the Centro de Investigación Médica Aplicada (CIMA, Pamplona, Spain) and joined the institution in may 2019. In september, 2022, APL was promoted to Scientific Director at CIMA.
Laboratory funding has been obtained during these years through different competitive national (GVA, MEC/MICINN/MINECO, ISCIII, Fundación Genoma España, etc.) and international (MSCA actions, ERA-NETs, European Science Foundation, H2020, etc.) agencies/calls, as well as from private institutions (Fundación Mutua Madrileña, Fundación GentxGent, Fundación para la Investigación en Urología, Fundación Fuentes Dutor, etc.). The group maintain very active collaborations with Hospitals (Hospital Universitario y Politécnico La Fe, Hospital Clínic de Barcelona, Instituto Valenciano de Oncología, Hospital 12 de Octubre, Clínica Universidad de Navarra, etc.), pharmaceutical (Janssen-Cilag, AstraZeneca, Moderna, Roche, etc.), and technological (Bruker BioSpin) companies, as well as with different investment funds (Ysios Capital, Asabys Partners, HealthTech 180, Columbus Venture Partners, Inveready, SODENA, etc.). APL ́s current interests focus on taking advantage of the collective knowledge developed over the last 15 years in different areas (omics, bioinformatics, nmr, molecular biology, protein chemistry, cell biology, in-vitro/in-vivo studies, computational chemistry, drug design, etc.) to tackle unmet clinical needs in different therapeutic areas.
研究兴趣
论文共 155 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Sandra P Nunes,Lucia Morales,Carolina Rubio,Ester Munera-Maravilla,Iris Lodewijk,Cristian Suárez-Cabrera,Victor G Martínez,Mercedes Pérez-Escavy,Miriam Pérez-Crespo, Miguel Alonso Sánchez, Esther Montesinos,Edurne San José-Enériz,
Cell death discoveryno. 1 (2024): 1-1
Daniel Orive, Mirari Echepare, Franco Bernasconi-Bisio,Miguel Fernández Sanmamed,Antonio Pineda-Lucena, Carlos de la Calle-Arroyo,Frank Detterbeck,Rayjean J. Hung, Mattias Johansson, Hilary A. Robbins, Luis M Seijo, Luis M Montuenga,
Archivos de Bronconeumología (2024)
Uxia Veleiro,Jesus de la Fuente,Guillermo Serrano,Marija Pizurica, Mikel Casals,Antonio Pineda-Lucena,Silve Vicent,Idoia Ochoa,Olivier Gevaert,Mikel Hernaez, Jonathan Wren
Edurne San José-Enériz,Naroa Gimenez-Camino, Obdulia Rabal,Leire Garate,Estibaliz Miranda, Nahia Gómez-Echarte,Fernando García,Stella Charalampopoulou,Elena Sáez,Amaia Vilas-Zornoza,Patxi San Martín-Uriz,Luis V. Valcárcel,
Nature Communicationsno. 1 (2024): 1-23
Cancer Researchno. 7_Supplement (2023): 5117-5117
Alejandro Fernandez-Montero, Jon Zuaznabar, Manuel Pina-Sanchez,Sheila Maestro, Loreto Martin-Navarro, Natalia Muñoz-Rodríguez,Cristina Olagüe,Marta Pastrana, Maria Martínez-Fernández,Gracian Camps,Jose Antonio Rodriguez,Francesco P. Marchese,
Nature Communicationsno. 1 (2023): 1-19
Garrido-Jareño Marta,Sahuquillo-Arce José Miguel, Rodríguez-Vega Héctor,Lloret-Sos Carmen,Gil-Brusola Ana,López-Hontangas José Luis,Nuñez-Beltran María,Tortosa-Carreres Jordi,García-García José Ángel,Cordón Lourdes,Puchades-Carrasco Leonor, de Santivañes Carmen Carreras-Gil,
BIOMEDICINE & PHARMACOTHERAPY (2023): 115882-115882
加载更多
作者统计
#Papers: 151
#Citation: 3505
H-Index: 32
G-Index: 53
Sociability: 7
Diversity: 0
Activity: 1
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn